Caroline Popper MD MPH

Dr. Popper serves as Senior Advisor in Outcome Capital’s molecular diagnostics and biotechnology practices. She brings significant expertise and track record in positioning novel technologies toward successful implementation and commercialization. Dr. Popper is also the Co-Founder and President of Popper and Company, a specialty consulting firm focused in diagnostics, information-generating tools and healthcare analytics, where she and her team leverage their extensive knowledge of the trends and forces shaping the life sciences industry and its participants.

Dr. Popper has more than 25 years of hands-on biotech/life sciences operating experience. An internist and pathologist, she combines medical and scientific perspective with knowledge gained from managing a wide spectrum of life sciences businesses in diagnostics, devices and drug discovery. Her business management experience in both Fortune 500 and start-up settings – and extensive track record creating strategic and business partnerships in the biotech arena – is key to the insights she provides to her clients.

During a 10-year career at Becton Dickinson (NYSE: BDX), Dr. Popper’s global responsibilities included clinical affairs, marketing, strategy, and business development. She was the founding General Manager of BDGene, a start-up focused, with its partner Millennium Pharmaceuticals, on development of novel cancer diagnostics. Subsequently, she was the Chief Business Officer for MDS Proteomics, a drug discovery company with operations in the U.S., Canada and Europe.

Dr. Popper received her medical degree from the University of the Witwatersrand (South Africa) and her M.P.H. from Johns Hopkins University (Baltimore). She completed her residencies in internal medicine and in pathology at Johns Hopkins. Dr. Popper is and Advisory Board member of the Bloomberg Johns Hopkins School and Public Health and inHealth, the Hopkins Precision Medicine Initiative. She is a board member of Diversigen (a microbiome-based company) and LBT Innovations (an Australian AI-based lab automation company).